Alcon acquired a majority interest in Aurion Biotech, a clinical-stage company developing advanced cell therapies to treat eye diseases ... a treatment for corneal edema, or swelling of the ...

1D) in eyes compromised AC visualization secondary to corneal edema or opacity. In their study of 62 eyes with AC inflammation, 91.6% of eyes with corneal edema (n=12) had identifiable ...

GENEVA, March 26, 2025--(BUSINESS WIRE)--Regulatory News: Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated ... into Phase 3 for corneal edema secondary to corneal endothelial disease ...